Dyslipidemia due to non-conforming lipid profiles poses an excellent risk of heart failure (CVD) in people with diabetes. Strong control requires a complete approach that includes lifestyle qualifications and pharmacological mediation. Lifestyle adaptations, including a healthy diet and upgraded bodily avocation, play an important role in coping with dyslipidemia. Abstinence from food reduces saturated fat, trans fat, and cholesterol, integrated with extreme-fiber elements and end-three oily acids, facilitating lipid sketches. Regular upsetting increases the levels of extreme-mass lipoprotein (HDL) cholesterol, promotes a burden deficit, and aids in the dyslipidemia maneuver. While behavioral modifications are inadequate, pharmacological treatments have evolved the expected main. Statins form the cornerstone of dyslipidemia control in patients with diabetes despite standard lipid levels because of their potential to lower depressed-mass lipoprotein (LDL) cholesterol levels. Additional lipid-curbing sellers, in addition to ezetimibe, hostility acid sequestrants, and PCSK9 inhibitors, can be used in healing processes to help lipid profiles. The most recent improvements include new formulations of antidiabetic capsules that display friendly results on lipid limits in patients with diabetes. Sodium-glucose co-bearer-2 (SGLT-2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) immediately offer cardiovascular approval and assist in lipid decline. SGLT-2 inhibitors decrease LDL cholesterol and triglyceride levels, concurrently with the activity of GLP-1 RAs, usually aimed at triglyceride and LDL cholesterol levels.